Caption Management, LLC Krystal Biotech, Inc. Call Options Transaction History

Caption Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $7.46 Million - $9.12 Million	-42,700 Reduced 54.26%	36,000 $6.55 Million
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $8.62 Million - $10.3 Million	56,300 Added 251.34%	78,700 $14.5 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $1.9 Million - $3.16 Million	-17,600 Reduced 44.0%	22,400 $3.99 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $1.66 Million - $2.22 Million	17,300 Added 76.21%	40,000 $4.96 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $292,977 - $351,594	2,700 Added 13.5%	22,700 $2.63 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $1.57 Million - $2.61 Million	20,000 New	20,000 $2.35 Million

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.